Processing...
Clinical Trials for Melanoma
Search
Search
There are 157 active trials for advanced/metastatic melanoma.
Click on a trial to see more information.
157 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with HLA-A2–positive, tyrosinase-expressing metastatic melanoma (ECOG 0–1), including those progressed after checkpoint inhibitors and, if BRAF V600–mutant, after BRAF/MEK therapy, receive a single infusion of autologous T cells retrovirally engineered to express the 1383I TCR targeting tyrosinase/HLA-A2. Dose-escalation assesses safety/MTD and early activity signals; key exclusions include active/uncontrolled brain metastases, systemic steroids, significant organ dysfunction, and prior tyrosinase-directed immunotherapy.
ClinicalTrials.gov ID: NCT02870244
TrialFetch AI summary: Enrolls adults with unresectable/metastatic melanoma progressing after PD‑1/PD‑L1 therapy and other checkpoint inhibitor–responsive solid tumors for AB821 monotherapy, an IV CD8‑IL21 fusion immunotherapy that selectively activates IL‑21 signaling in CD8+ T cells to enhance cytotoxicity and T‑cell memory. Patients must have ECOG 0–1 and adequate organ function; key exclusions include active autoimmune disease requiring treatment, untreated/unstable CNS metastases, significant cardiovascular disease, chronic immunosuppression, and prior IL‑21–based therapy.
ClinicalTrials.gov ID: NCT07027488
TrialFetch AI summary: Enrolling adults (and ≥12 in one cohort) with unresectable stage III/IV melanoma that has progressed after anti–PD-1/PD-L1 therapy (and after BRAF±MEK for V600-mutant), excluding ocular or active CNS disease and >2 prior systemic lines. Intratumoral KB707, an oncolytic HSV-1 engineered to express IL-12 and IL-2, is given with checkpoint blockade (Opdualag or pembrolizumab) to enhance local/systemic antitumor immunity.
ClinicalTrials.gov ID: NCT05970497
TrialFetch AI summary: Adults with advanced solid tumors driven by MAPK pathway alterations, including cohorts for NRAS‑mutant melanoma, BRAF‑altered melanoma/other tumors, KRAS/NRAS‑mutant non‑melanoma cancers, and BRAF‑altered glioma, receive once‑daily oral NST‑628. NST‑628 is an investigational, brain‑penetrant pan‑RAF/MEK molecular glue that stabilizes inactive RAF–MEK complexes to block MEK/ERK signaling; prior BRAF/MEK inhibitor exposure is excluded in expansion cohorts.
ClinicalTrials.gov ID: NCT06326411
TrialFetch AI summary: Adults with unresectable stage III/IV melanoma (ECOG 0–1), including PD‑1–naïve, previously treated, or PD‑1–refractory cohorts, receive nivolumab plus hydroxychloroquine (an autophagy/lysosomal inhibitor) or nivolumab/ipilimumab plus hydroxychloroquine. Aims include defining HCQ dose with PD‑1/CTLA‑4 blockade and assessing response to nivolumab+HCQ, with key exclusions for active severe autoimmune disease, unstable CNS disease, and significant comorbidities.
ClinicalTrials.gov ID: NCT04464759
TrialFetch AI summary: Adults with metastatic or unresectable BRAF V600–mutant melanoma who are stable on or have progressed after prior BRAF/MEK therapy receive standard dabrafenib/trametinib or encorafenib/binimetinib with added nilotinib. Nilotinib (a BCR-ABL/c-KIT/PDGFR tyrosine kinase inhibitor) is dose-escalated to assess safety, pharmacokinetics, and preliminary activity of this triplet strategy; treated, stable brain metastases allowed.
ClinicalTrials.gov ID: NCT04903119
TrialFetch AI summary: Adults with unresectable stage III–IV melanoma (ECOG 0–2), including PD-1–naïve metastatic patients or those with stable/partial response on ongoing PD-1 after ≥12 weeks and prior adjuvant checkpoint or BRAF/MEK allowed; excludes active diabetes requiring meds, active CNS disease, significant immunosuppression, or autoimmune disease needing systemic therapy. Patients receive pembrolizumab alone or pembrolizumab plus metformin (AMPK activator/mitochondrial complex I inhibitor aimed at reversing T-cell metabolic insufficiency) to assess immunometabolic and clinical benefit.
ClinicalTrials.gov ID: NCT03311308
TrialFetch AI summary: Adults with advanced/metastatic solid tumors (ECOG 0–1) after standard therapy failure; phase 1 tests oral GIM‑531 monotherapy (including NSCLC, TNBC, platinum‑resistant ovarian, and AKT3‑altered tumors), and phase 2 treats melanoma, NSCLC, or RCC that progressed on anti‑PD‑1 with continued anti‑PD‑1 plus GIM‑531. GIM‑531 is a first‑in‑class, Treg‑selective small‑molecule inhibitor linked to AKT3/PI3K–AKT pathway modulation to suppress Tregs and potentially restore antitumor immunity.
ClinicalTrials.gov ID: NCT06425926
TrialFetch AI summary: Adults with metastatic cutaneous melanoma, including those refractory to prior PD-1/PD-L1 therapy and with at least one resectable lesion for TIL harvest, receive non-myeloablative lymphodepletion followed by autologous TIL infusion and high-dose IL-2, with most eligible patients also receiving pembrolizumab (anti–PD-1) given peri- and post-infusion. Patients with controlled small asymptomatic brain metastases may enroll; key exclusions include significant autoimmune disease, active infections, major cardiopulmonary compromise, and prior severe immune-related toxicities to PD-1/PD-L1 agents for the pembrolizumab arm.
ClinicalTrials.gov ID: NCT02621021
TrialFetch AI summary: Adults with unresectable stage III–IV cutaneous melanoma (non-uveal), treatment-naïve for metastatic disease, receive ipilimumab plus fixed-dose nivolumab/relatlimab with added sarilumab, an interleukin‑6 receptor–blocking antibody intended to mitigate immune-related toxicity and potentially enhance efficacy. Excludes active/untreated brain metastases, active autoimmune disease requiring systemic therapy, and significant immunosuppression.
ClinicalTrials.gov ID: NCT05428007